Baader Bank Aktiengesellschaft Takes Position in Ionis Pharmaceuticals, Inc. $IONS

Baader Bank Aktiengesellschaft acquired a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 10,228 shares of the company’s stock, valued at approximately $668,000.

Other large investors have also recently bought and sold shares of the company. Golden State Wealth Management LLC increased its holdings in Ionis Pharmaceuticals by 198.4% in the 3rd quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock worth $25,000 after buying an additional 250 shares during the period. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter valued at $25,000. Mather Group LLC. purchased a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter valued at $27,000. Meeder Asset Management Inc. increased its stake in shares of Ionis Pharmaceuticals by 620.2% in the third quarter. Meeder Asset Management Inc. now owns 713 shares of the company’s stock worth $47,000 after acquiring an additional 614 shares during the period. Finally, Allworth Financial LP raised its holdings in shares of Ionis Pharmaceuticals by 231.8% during the second quarter. Allworth Financial LP now owns 740 shares of the company’s stock worth $29,000 after purchasing an additional 517 shares during the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Analyst Ratings Changes

IONS has been the subject of a number of research reports. Bank of America boosted their target price on shares of Ionis Pharmaceuticals from $86.00 to $97.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. TD Cowen reissued a “buy” rating on shares of Ionis Pharmaceuticals in a report on Wednesday, December 3rd. Morgan Stanley raised their target price on Ionis Pharmaceuticals from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. Raymond James Financial reiterated a “strong-buy” rating and set a $89.00 price target (up from $85.00) on shares of Ionis Pharmaceuticals in a research report on Thursday, October 30th. Finally, Piper Sandler upped their price objective on Ionis Pharmaceuticals from $77.00 to $87.00 and gave the stock an “overweight” rating in a research report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $86.95.

Insider Transactions at Ionis Pharmaceuticals

In other news, EVP Shannon L. Devers sold 44,199 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $85.08, for a total value of $3,760,450.92. Following the transaction, the executive vice president directly owned 17,494 shares of the company’s stock, valued at approximately $1,488,389.52. This trade represents a 71.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Eric Swayze sold 23,463 shares of the company’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $79.12, for a total transaction of $1,856,392.56. Following the sale, the executive vice president directly owned 30,453 shares of the company’s stock, valued at approximately $2,409,441.36. This represents a 43.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 460,714 shares of company stock worth $37,295,131 in the last quarter. 2.60% of the stock is owned by insiders.

Ionis Pharmaceuticals Stock Up 0.1%

IONS opened at $84.35 on Thursday. The company has a market cap of $13.66 billion, a PE ratio of -49.91 and a beta of 0.29. Ionis Pharmaceuticals, Inc. has a twelve month low of $23.95 and a twelve month high of $86.74. The company has a 50-day moving average price of $80.72 and a 200 day moving average price of $68.75. The company has a quick ratio of 2.78, a current ratio of 2.79 and a debt-to-equity ratio of 0.96.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.